992.6000 -3.70 (-0.37%)
NSE Jun 12, 2025 15:48 PM
Volume: 212.6K
 

992.60
-0.37%
ICICI Securities Limited
Alembic reported a healthy 17.7% YoY revenue growth driven by traction in the export business and APIs. Operational cost of three new plants impacted margins. Management does not expect any material escalation in overhead costs ahead. Company has launched only 5 products (15-20 filed) from the three new sites, which may not be able to improve profitability in the near term.
Alembic Pharmaceuticals Ltd. is trading above its 150 day SMA of 953.3
More from Alembic Pharmaceuticals Ltd.
Recommended